What is the management and treatment for a kidney with a duplicated renal moiety (double moiety) and impaired perfusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The management of a kidney with a duplicated renal moiety and impaired perfusion should prioritize revascularization with primary balloon angioplasty and bailout stenting, especially in cases with hypertension and/or signs of renal dysfunction due to renal artery stenosis caused by fibromuscular dysplasia, as recommended by the 2024 ESC guidelines 1.

Initial Assessment and Treatment

The initial approach involves a comprehensive assessment of the patient's condition, including the extent of renal impairment and the underlying cause of poor perfusion. Optimizing blood pressure with medications such as ACE inhibitors or ARBs is crucial to maintain adequate renal perfusion without causing hypotension, as suggested by general medical principles. Ensuring adequate hydration while avoiding volume overload is also vital, typically through careful fluid management targeting euvolemia.

Revascularization Considerations

Revascularization should be considered in patients with atherosclerotic unilateral >70% renal artery stenosis (RAS), concomitant high-risk features, and signs of kidney viability, as per the 2024 ESC guidelines for the management of peripheral arterial and aortic diseases 1. This approach is particularly relevant for patients with hypertension and/or signs of renal dysfunction due to RAS caused by fibromuscular dysplasia, where revascularization with primary balloon angioplasty and bailout stenting is recommended 1.

Monitoring and Follow-Up

Regular monitoring of renal function with serum creatinine, BUN, and estimated GFR every 1-3 months is essential to assess the effectiveness of the treatment and the progression of renal impairment. Imaging follow-up with renal ultrasound every 3-6 months helps evaluate changes in hydronephrosis or further deterioration, guiding the need for adjustments in the treatment plan.

Surgical Interventions

In cases where revascularization is not feasible or has failed, open surgical revascularization should be considered, especially in patients with complex anatomy or after failed endovascular revascularization, as suggested by the guidelines 1. For cases with significant obstruction causing the perfusion issues, drainage procedures such as ureteral stent placement or percutaneous nephrostomy may be necessary. In severe cases with irreversible damage to one moiety and preserved function in the other, partial nephrectomy of the poorly functioning segment might be considered to prevent recurrent infections and other complications.

From the Research

Management and Treatment

The management and treatment of a kidney with a duplicated renal moiety (double moiety) and impaired perfusion is not directly addressed in the provided studies. However, some studies discuss the management of related conditions, such as chronic kidney disease (CKD) and acute kidney injury (AKI).

Related Conditions

  • CKD is a condition where the kidneys lose their function over time, and it can be associated with high mortality and morbidity 2.
  • AKI is a sudden loss of kidney function, and it can be caused by various factors, including ischemia-reperfusion injury (IRI) 3.
  • Impaired renal perfusion can be a consequence of AKI, and it can worsen renal outcome despite reduced glomerulosclerosis 3.

Treatment Strategies

  • Antihypertensive treatment can be used to manage blood pressure in patients with CKD, but it may not always be effective in improving renal outcomes 3, 4.
  • Renin-angiotensin-aldosterone axis inhibitor therapy can be beneficial in patients with mild-to-moderate CKD, but it may not be used in all suitable patients due to fear of hyperkalemia and worsening kidney function 2.
  • Sodium-glucose cotransporter inhibitor therapy can improve mortality and hospitalization in patients with heart failure and CKD stages 3 and 4 2.
  • A multidisciplinary approach, including combined cardiology-nephrology clinics, may be necessary for the implementation of evidence-based therapy in patients with CKD and heart failure 2.

Anticoagulation Strategies

  • Anticoagulation strategies, such as unfractionated heparin, regional citrate anticoagulation, and low-molecular weight heparin, can be used in patients with CKD, but the choice of anticoagulant should be determined by patient characteristics, local expertise, and ease of monitoring 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of Heart Failure Patient with CKD.

Clinical journal of the American Society of Nephrology : CJASN, 2021

Research

Early antihypertensive treatment and ischemia-induced acute kidney injury.

American journal of physiology. Renal physiology, 2020

Research

Renal microvascular dysfunction, hypertension and CKD progression.

Current opinion in nephrology and hypertension, 2013

Research

Anticoagulant use in patients with chronic renal impairment.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.